Bruker Corporation Company Profile (NASDAQ:BRKR)

Bruker Corporation trades on the NASDAQ under the ticker symbol "BRKR."

Bruker Corporation announced a quarterly dividend on Monday, August 14th. Investors of record on Tuesday, September 5th will be given a dividend of $0.04 per share on Friday, September 22nd. This represents a $0.16 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend is Thursday, August 31st. View Bruker Corporation's Dividend History.

Bruker Corporation declared that its board has approved a stock buyback plan on Sunday, June 4th 2017, which permits the company to repurchase $225,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.

Bruker Corporation (NASDAQ:BRKR) announced its earnings results on Thursday, August, 3rd. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. The company had revenue of $414.90 million for the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. The business's revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.20 earnings per share. View Bruker Corporation's Earnings History.

Bruker Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Bruker Corporation.

Bruker Corporation issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $1.08 to $1.12 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.10. The company issued revenue guidance of +4.5-6% to $1.68-1.71 billion, compared to the consensus revenue estimate of $1.68 billion.

12 brokerages have issued twelve-month target prices for Bruker Corporation's stock. Their forecasts range from $20.00 to $30.00. On average, they expect Bruker Corporation's stock price to reach $26.25 in the next year. View Analyst Ratings for Bruker Corporation.

Here are some recent quotes from research analysts about Bruker Corporation stock:

• 1. According to Zacks Investment Research, "Bruker’s latest spree of product development is encouraging, the latest launch being the AVANCE NEO platform, a next-generation NMR console. The company’s strategic acquisition activity also encourages us. Also the cost-reduction action previously adopted by the company in its Nano-surfaces business played its role suitably. The company's solid cash balance on the back of improved free cash flow is indicative of strong fundamentals. Above all, the company’s raised revenue guidance also holds optimism indicating promising performance ahead. On the flip side, over the last one year, Bruker is trading below the Zacks categorized Instruments-Scientific industry. We are also discouraged with the company's year-over-year decline in organic revenues in the last reported first quarter. We are also concerned about currency fluctuations, competitive landscape and macroeconomic headwinds which are the major woes for Bruker." (7/6/2017)
• 2. Jefferies Group LLC analysts commented, "4Q16 EPS walloped consensus (+9c / +4c operational), while the initial 2017 EPS outlook bracketed consensus. Commentary pointed to further signs of endmarket stability as EU orders turned positive in 4Q (first time all yr). Net-net, BRKR is managing the P&L better than it ever has, and with end-mkts steadily improving, we like the risk/reward & see room for upside. We modestly raise our '17/18 EPS by +1c/+5c (to $1.08/$1.30)." (2/14/2017)
• 3. Evercore ISI analysts commented, "Bruker continues to execute well across its business, delivering on impressive GM expansion, while continuing OpEx rationalization and stepping up capital allocation. Thus in terms of what management can control they are doing an excellent job and certainly have delivered much of what shareholders demanded several years ago. That being said end markets remain not fully cooperative, and while EU academic has improved it is off of depressed levels. Given this dynamic core growth remains constrained and in a year where the growth comparable is tough due to tax savings the current outlook for EPS upside is mixed. With shares trading north of 20x we contend that visibility back to 3-5% core growth must improve, and we look for further check points from management in the first part of 2017. We think if bookings momentum continues to accelerate over the next few quarters that will be the signal to get incrementally constructive on shares. Therefore we await additional proof points and in the near-term remain on the sidelines." (2/14/2017)
• 4. Cantor Fitzgerald analysts commented, "CytoSorbents announced that the company has now received a permanent, dedicated, reimbursement procedure code for CytoSorb in Germany." This is positive news." (12/7/2016)

Some companies that are related to Bruker Corporation include PerkinElmer (PKI), ABIOMED (ABMD), Alere (ALR), Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO) and Neovasc (NVCN).

Bruker Corporation's management team includes the folowing people:

• Frank H. Laukien Ph.D., Chairman of the Board, President, Chief Executive Officer
• Anthony L. Mattacchione, Chief Financial Officer, Senior Vice President
• Juergen Srega, President of Bruker CALID Group and Bruker Daltonics Division
• Mark Robert Munch Ph.D., Executive Vice President - President of Bruker Nano Group and Bruker Nano Surfaces Division
• William A. Linton, Lead Independent Director
• Joerg C. Laukien, Director
• Cynthia M. Friend Ph.D., Independent Director
• Marc A. Kastner Ph.D., Independent Director
• Richard D. Kniss, Independent Director

Bruker Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.04%), FMR LLC (4.22%), Acadian Asset Management LLC (3.20%), BlackRock Inc. (2.97%), Boston Partners (1.74%) and Alliancebernstein L.P. (1.36%). Company insiders that own Bruker Corporation stock include Frank H Laukien, Ingen Chris Van, Joerg C Laukien, Mark Munch, Richard A Packer, Richard Kniss and Wolf-Dieter Emmerich. View Institutional Ownership Trends for Bruker Corporation.

Bruker Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Cambiar Investors LLC, Alliancebernstein L.P., Acadian Asset Management LLC, JPMorgan Chase & Co., BTIM Corp., Goldman Sachs Group Inc. and Vanguard Group Inc.. Company insiders that have sold Bruker Corporation stock in the last year include Ingen Chris Van, Mark Munch and Richard Kniss. View Insider Buying and Selling for Bruker Corporation.

Bruker Corporation's stock was bought by a variety of institutional investors in the last quarter, including AJO LP, Koch Industries Inc., Arrowstreet Capital Limited Partnership, PDT Partners LLC, Marshall Wace North America L.P., BlackRock Inc., New York State Common Retirement Fund and Victory Capital Management Inc.. Company insiders that have bought Bruker Corporation stock in the last two years include Frank H Laukien and Richard A Packer. View Insider Buying and Selling for Bruker Corporation.

Shares of Bruker Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Bruker Corporation stock can currently be purchased for approximately $29.70.